Information Provided By: 
Fly News Breaks for November 16, 2016
ADHD
Nov 16, 2016 | 08:45 EDT
Roth Capital analyst Michael Higgins notes that since the announcement that the FDA was placing a clinical hold on Alcobra's Phase 3 pivotal trial, MEASURE, the company has been preparing for a meeting with the agency. The analyst is confident MEASURE's clinical hold will be lifted since metadoxine has been used for 40 years in millions of patients with no prior human evidence of nerve conduction problems. He reiterates a Buy rating and $7.50 price target on the shares.
News For ADHD From the Last 2 Days
There are no results for your query ADHD
